Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology is discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing the life expectancy WW. However, this has not translated into any reduction in the incidence or prevalence of chronic or critical illnesses! On the contrary the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise!. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of trillion dollar mark by 2020 By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic have reached a critical mass warranting a close watch for those interested in keeping pace with the development of new medicines.
EXECUTIVE SUMMARY
Dawn of the Golden Era for Regenerative Medicine/Stem cell based therapies
INTRODUCTION
Stem cells Types
Mesenchymal stem cells (MSCs)
TOUGH CHOICE- 'AUTOLOGOUS VS. ALLOGENIC' THERAPIES
REGULATORY GUIDELINES
Japan and Asia Lead the Way
Japanese Adaptive Licensing Legislation
South Korea Regulatory Update
India Regulatory Update
Regulatory Scenario in US and EU
MARKETED CELL BASED/STEM CELL PRODUCTS
Approved Cell-based / Stem Cell Therapies in Korea and WW
Cost of Treatment of Approved Therapies
PROGRESS AND CHALLENGES
Reimbursement of Approved Cell based Therapies!
MERGER AND ACQUISITION- GAINING MOMENTUM IN REGENERATIVE SPACE
PROGRESS IN SPECIFIC THERAPY AREAS
Diabetes
Cardiovascular Disease
Musculoskeletal (MSD) Related Conditions
Ocular Disease
SELECT UPCOMING MILESTONES IN REGENERATIVE MEDICINE/STEM CELL FOCUSED COMPANIES (2015-16)
APPENDIX
Dawn of the Golden Era for Regenerative Medicine/Stem cell based therapies
INTRODUCTION
Stem cells Types
Mesenchymal stem cells (MSCs)
TOUGH CHOICE- 'AUTOLOGOUS VS. ALLOGENIC' THERAPIES
REGULATORY GUIDELINES
Japan and Asia Lead the Way
Japanese Adaptive Licensing Legislation
South Korea Regulatory Update
India Regulatory Update
Regulatory Scenario in US and EU
MARKETED CELL BASED/STEM CELL PRODUCTS
Approved Cell-based / Stem Cell Therapies in Korea and WW
Cost of Treatment of Approved Therapies
PROGRESS AND CHALLENGES
Reimbursement of Approved Cell based Therapies!
MERGER AND ACQUISITION- GAINING MOMENTUM IN REGENERATIVE SPACE
PROGRESS IN SPECIFIC THERAPY AREAS
Diabetes
Cardiovascular Disease
Musculoskeletal (MSD) Related Conditions
Ocular Disease
SELECT UPCOMING MILESTONES IN REGENERATIVE MEDICINE/STEM CELL FOCUSED COMPANIES (2015-16)
APPENDIX
